Renal Denervation Systems Market Size Worth US$ 1,723.6 Million by 2027 | CAGR 40.67%

IMARC Group, a leading market research company, has recently releases report titled "Renal Denervation Systems Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" The study provides a detailed analysis of the industry, including the global renal denervation systems market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the renal denervation systems market?

The global renal denervation systems market size reached US$ 218.2 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,723.6 Million by 2027, exhibiting a growth rate (CAGR) of 40.67% during 2022-2027.

What is renal denervation systems?

Renal denervation (RDN) refers to a minimally invasive,catheter-based procedure that is performed to treat resistant hypertension. It involves a radiofrequency ablation, which burns the nerves within the renal arteries. This, in turn, suppresses the nerve activity and modulates the output of the sympathetic nerves, thereby assisting in decreasing the blood pressure. In addition to this, it lowers renin secretion, improves blood flow, and stimulates natriuresis. Consequently, RDN systems is being widely adopted to treat hypertension coexisting with metabolic abnormalities, sleep apnea, heart failure, chronic kidney disease, and arrhythmias.

Request for a free sample copy of this report: https://www.imarcgroup.com/renal-denervation-systems-market/requestsample

What are the growth prospects and trends in the renal denervation systems industry?

The global RDN systems market is majorly being driven by the growing instances of lifestyle-related disorders, such as therapy-resistant hypertension, due to sedentary lifestyle, evolving dietary habits, and the increasing cigarette smoking population. This is further supported by the rising geriatric population, which is more susceptible to developing such ailments. Moreover, the growingawareness regarding the clinical advantages associated with RDN systems, including quick recovery, cost-effectiveness, and minimal complications are also facilitating the product demand across the globe. Other than this, continuous investments in research and development (R&D) activities to introduce alternative technologies for RDN, such as micro-infusion, is acting as another growth-inducing factor. Additionally, increasing clinical trials to validate clinical efficiency of RDN over conventional surgeries are creating a positive outlook for the market further. Looking forward, the market is expected to grow at a CAGR of 40.67% during 2022-2027.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Product Type:

Catheters
Single Electrode Catheter
Multi Electrode Catheter
RF Generator
Nerve Modifying Agents

Breakup by Product:

Symplicity
Vessix (V2)
EnligHTN
Paradise
Iberis
Others

Breakup by Technology:

Ultrasound Ablation
Radiofrequency Ablation
Microinfusion

Breakup by Application:

Hypertension
Cardiac Disorders
Diabetes
Renal Failure
Others

Breakup by End User:

Diagnostic Centers and Hospitals
Ambulatory Care Centers
Others

Breakup by Region:

North America (U.S. & Canada)
Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
Latin America (Brazil, Mexico)
Middle East & Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Boston Scientific Group
Kona Medical Inc.
Medtronic Plc
Mercator MedSystems
ReCor Medical Inc. (Otsuka Holdings Co. Ltd.)
Renal Dynamics
St. Jude Medical Inc. (Abbott)
Terumo Corporation.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=2558&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.